Fulvio G, Baldini C, Mosca M, Di Paolo A, Bocci G, Palumbo G
Front Med (Lausanne). 2023; 10:1254868.
PMID: 37915324
PMC: 10616863.
DOI: 10.3389/fmed.2023.1254868.
Li T, Zhang Y
Turk J Haematol. 2023; 40(1):77-79.
PMID: 36849726
PMC: 9979730.
DOI: 10.4274/tjh.galenos.2023.2022.0384.
Luque Paz D, Kralovics R, Skoda R
Blood. 2022; 141(16):1909-1921.
PMID: 36347013
PMC: 10646774.
DOI: 10.1182/blood.2022017578.
Rauch P, Ebert B
JACC CardioOncol. 2022; 4(1):50-52.
PMID: 35492812
PMC: 9040111.
DOI: 10.1016/j.jaccao.2022.01.094.
Markovic D, Maslovaric I, Djikic D, cokic V
Int J Mol Sci. 2022; 23(3).
PMID: 35163413
PMC: 8836089.
DOI: 10.3390/ijms23031490.
A Novel Megakaryocyte Subpopulation Poised to Exert the Function of HSC Niche as Possible Driver of Myelofibrosis.
Migliaccio A
Cells. 2021; 10(12).
PMID: 34943811
PMC: 8699046.
DOI: 10.3390/cells10123302.
Application of Single-Cell Approaches to Study Myeloproliferative Neoplasm Biology.
Royston D, Mead A, Psaila B
Hematol Oncol Clin North Am. 2021; 35(2):279-293.
PMID: 33641869
PMC: 7935666.
DOI: 10.1016/j.hoc.2021.01.002.
Overview of Myeloproliferative Neoplasms: History, Pathogenesis, Diagnostic Criteria, and Complications.
Tremblay D, Yacoub A, Hoffman R
Hematol Oncol Clin North Am. 2021; 35(2):159-176.
PMID: 33641861
PMC: 8669599.
DOI: 10.1016/j.hoc.2020.12.001.
Reconstructing the Lineage Histories and Differentiation Trajectories of Individual Cancer Cells in Myeloproliferative Neoplasms.
Van Egeren D, Escabi J, Nguyen M, Liu S, Reilly C, Patel S
Cell Stem Cell. 2021; 28(3):514-523.e9.
PMID: 33621486
PMC: 7939520.
DOI: 10.1016/j.stem.2021.02.001.
Clonal Hematopoiesis and Mutations of Myeloproliferative Neoplasms.
Kjaer L
Cancers (Basel). 2020; 12(8).
PMID: 32731609
PMC: 7464548.
DOI: 10.3390/cancers12082100.
Polycythaemia Vera JAK 2 Mutation in a Patient with Underlying Chronic Obstructive Pulmonary Disease at a Primary Care Setting.
Mahmud R, Ariffin F, Shanmuganathan P
Korean J Fam Med. 2020; 41(4):263-266.
PMID: 32512984
PMC: 7385292.
DOI: 10.4082/kjfm.18.0161.
Clonal hematopoiesis as a model for premalignant changes during aging.
Steensma D, Ebert B
Exp Hematol. 2019; 83:48-56.
PMID: 31838005
PMC: 7103509.
DOI: 10.1016/j.exphem.2019.12.001.
Novel targets to cure primary myelofibrosis from studies on Gata1 mice.
Zingariello M, Martelli F, Verachi P, Bardelli C, Gobbo F, Mazzarini M
IUBMB Life. 2019; 72(1):131-141.
PMID: 31749302
PMC: 7256843.
DOI: 10.1002/iub.2198.
Novel strategies for the treatment of myelofibrosis driven by recent advances in understanding the role of the microenvironment in its etiology.
Eran Z, Zingariello M, Bochicchio M, Bardelli C, Migliaccio A
F1000Res. 2019; 8.
PMID: 31583083
PMC: 6758840.
DOI: 10.12688/f1000research.18581.1.
Clinical consequences of clonal hematopoiesis of indeterminate potential.
Steensma D
Hematology Am Soc Hematol Educ Program. 2018; 2018(1):264-269.
PMID: 30504320
PMC: 6245996.
DOI: 10.1182/asheducation-2018.1.264.
Clinical consequences of clonal hematopoiesis of indeterminate potential.
Steensma D
Blood Adv. 2018; 2(22):3404-3410.
PMID: 30482770
PMC: 6258914.
DOI: 10.1182/bloodadvances.2018020222.
A vicious interplay between genetic and environmental insults in the etiology of blood cancers.
Migliaccio A
Exp Hematol. 2017; 59:9-13.
PMID: 29248611
PMC: 6381597.
DOI: 10.1016/j.exphem.2017.12.004.
Myeloproliferative neoplasms: from origins to outcomes.
Nangalia J, Green A
Hematology Am Soc Hematol Educ Program. 2017; 2017(1):470-479.
PMID: 29222295
PMC: 6142568.
DOI: 10.1182/asheducation-2017.1.470.
Overview of Transgenic Mouse Models of Myeloproliferative Neoplasms (MPNs).
Dunbar A, Nazir A, Levine R
Curr Protoc Pharmacol. 2017; 77:14.40.1-14.40.19.
PMID: 28640953
PMC: 6352313.
DOI: 10.1002/cpph.23.
Epigenetic dysregulation of hematopoietic stem cells and preleukemic state.
Kunimoto H, Nakajima H
Int J Hematol. 2017; 106(1):34-44.
PMID: 28555413
DOI: 10.1007/s12185-017-2257-6.